Vicks expands Sinex portfolio to offer targeted solutions to treat sinus symptoms
“The Clear Your Head Medicine” is poised to lead the sinus category, offering clarity in a confusing allergy and cold aisle.
Sinus sufferers can now breathe a sigh of relief as Vicks, the makers of NyQuil and DayQuil, has announced the relaunch and expansion of its Sinex brand, a complete line of over-the-counter (OTC) medications designed for consumers who suffer from sinus symptoms. With the relaunch, “The Clear Your Head Medicine” enters a misunderstood category to offer consumers a clear choice for their nasal congestion and pressure relief, regardless of whether symptoms are due to allergies, colds or other triggers.
Consumers can experience confusion when they’re trying to find a product that can offer total sinus relief, partly because our research has found that sinus lacks a true category leader. Without that well-known, go-to sinus brand, people are left to juggle a variety of products to find relief for their symptoms,” explained Dave Tomasi, Commercial Director, P&G Personal Health Care. “With 63% of sinus sufferers looking to a variety of medications that might not do the job for their sinus symptoms, this expansion of the Sinex line will offer one-stop-shop relief from a trusted brand.”
Seventy-one percent of US households (85 million) suffer from sinus symptoms in a given year, while 17% of US households (20 million) are severe sinus sufferers. This relaunch marks more than 50 years of the Vicks presence in the OTC sinus segment and more than 100 years as a trusted cough, cold and flu brand. Available this month, Vicks Sinex now offers a complete product lineup with both sprays and LiquiCaps including
Originally, launched in 1959 as “Medi Mist,” the brand adopted the name Sinex 3 years later and was the market leader through the mid-1990s. Although additional products have since entered the nasal spray market, Sinex has retained high awareness and a loyal following due to its “long-lasting relief” claim and the introduction of the first Ultra Fine Mist in the 1990s. Since the mid-90s, the brand has offered fast-acting relief in nasal spray form.
“There are many well-established brands for allergy relief but without that true category leader for consumers who suffer from sinus symptoms, it made sense to launch a line specifically designed to address these consumers’ needs, regardless of the trigger. We want to keep it simple – Sinex stands for sinus,” added Dave Tomasi.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.